Marinomed Biotech AG reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was EUR 7.1 million compared to EUR 5.7 million a year ago. Net loss was EUR 5.8 million compared to EUR 6.3 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.1 EUR | 0.00% | +2.40% | -41.44% |
Apr. 16 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 | |
Apr. 16 | Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.44% | 28.38M | |
-2.61% | 88.47B | |
+3.55% | 40.71B | |
-14.40% | 32.43B | |
+55.89% | 24.28B | |
-15.96% | 15.52B | |
-41.29% | 12.17B | |
-15.50% | 12.01B | |
-11.75% | 12B | |
+7.87% | 8.87B |
- Stock Market
- Equities
- MARI Stock
- News Marinomed Biotech AG
- Marinomed Biotech AG Reports Earnings Results for the Nine Months Ended September 30, 2022